Access the full text.
Sign up today, get DeepDyve free for 14 days.
Kristen Pollizzi, J. Powell (2014)
Integrating canonical and metabolic signalling programmes in the regulation of T cell responsesNature Reviews Immunology, 14
Mingxin Zhang, Chao Zhang, Lingmin Zhang, Qi Yang, Suna Zhou, Q. Wen, Jing-Jie Wang (2015)
Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinomaBMC Cancer, 15
Jiang Chen, Yaojun Yu, Tong Ji, Rui Ma, Mingming Chen, Gaofeng Li, Feibo Li, Qiong Ding, Qingsong Kang, Diyu Huang, X. Liang, Hui Lin, Xiujun Cai (2016)
Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinomaCancer Medicine, 5
Dehyrogenase Phosphatase Catalytic Subunit 2
Phosphoglycerate Kinase 2; PGLS, 6-Phosphogluconolactonase
Pyruvate Dehydrogenase E1 Subunit Beta
Bo Zhu, Liming Tang, Shuyang Chen, Chengqian Yin, Shiguang Peng, Xin Li, Tongzheng Liu, W. Liu, Chang-Sung Han, L. Stawski, Zhi-xiang Xu, Guangbiao Zhou, Xiang Chen, Xiumei Gao, C. Goding, Nan Xu, Rutao Cui, P. Cao (2018)
Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapyOncogene, 37
S. Itoh, K. Shirabe, A. Taketomi, K. Morita, N. Harimoto, E. Tsujita, K. Sugimachi, Y. Yamashita, T. Gion, Y. Maehara (2012)
Zero mortality in more than 300 hepatic resections: validity of preoperative volumetric analysisSurgery Today, 42
Sai-Ching Yeung, Jingxuan Pan, Mong-Hong Lee (2008)
Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of CancerCellular and Molecular Life Sciences, 65
M. Marzec, Qian Zhang, Ami Goradia, P. Raghunath, Xiaobin Liu, M. Paessler, Hong Wang, M. Wysocka, M. Cheng, B. Ruggeri, M. Wasik (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences, 105
D. Woodfield (1986)
Hepatocellular carcinoma.The New Zealand medical journal, 99 795
G. DeNicola, Pei-Hsuan Chen, Edouard Mullarky, J. Sudderth, Zeping Hu, David Wu, Hao Tang, Yang Xie, J. Asara, K. Huffman, I. Wistuba, J. Minna, R. Deberardinis, L. Cantley (2015)
NRF2 regulates serine biosynthesis in non-small cell lung cancerNature genetics, 47
Chongbiao Huang, Yang Li, Zengxun Li, Yang Xu, Na Li, Y. Ge, Jie Dong, Antao Chang, Tiansuo Zhao, Xiuchao Wang, Hongwei Wang, Shengyu Yang, K. Xie, J. Hao, H. Ren (2019)
LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein TranslationClinical Cancer Research, 25
Anju Singh, Swetlana Boldin-Adamsky, R. Thimmulappa, S. Rath, H. Ashush, J. Coulter, A. Blackford, S. Goodman, F. Bunz, W. Watson, E. Gabrielson, E. Feinstein, S. Biswal (2008)
RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.Cancer research, 68 19
Xiaofeng Jiang, Jun Zhou, A. Giobbie-Hurder, J. Wargo, Stephen Hodi (2012)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 19
Phosphorylase Kinase Regulatory Subunit Beta
K. Izuishi, Y. Yamamoto, H. Mori, Riko Kameyama, S. Fujihara, T. Masaki, Yasuyuki Suzuki (2014)
Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer.Oncology reports, 31 2
S. Itoh, T. Yoshizumi, K. Yugawa, D. Imai, S. Yoshiya, K. Takeishi, T. Toshima, N. Harada, T. Ikegami, Y. Soejima, Kenichi Kohashi, Y. Oda, M. Mori (2020)
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular FormationHepatology, 72
S. Best, D. Souza, A. Kersbergen, A. Policheni, S. Dayalan, D. Tull, V. Rathi, D. Gray, Matthew Ritchie, M. McConville, K. Sutherland (2018)
Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.Cell metabolism, 27 4
Norifumi Iseda, S. Itoh, T. Yoshizumi, K. Yugawa, A. Morinaga, T. Tomiyama, T. Toshima, Kenichi Kohashi, Y. Oda, M. Mori (2020)
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular CarcinomaHepatology Communications, 5
M. Shimokawa, T. Yoshizumi, S. Itoh, Norifumi Iseda, Kazuhito Sakata, K. Yugawa, T. Toshima, N. Harada, T. Ikegami, M. Mori (2020)
Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinomaCancer Science, 111
Enolase 3; FBP1, Fructose-Bisphosphatase 1; FBP2, Fructose-Bisphosphatase 2; FH, Fumarate Hydratase; G6PC, Glucose-6-Phosphatase Catalytic Subunit
Y. Kitano, Y. Baba, S. Nakagawa, K. Miyake, M. Iwatsuki, T. Ishimoto, Y. Yamashita, N. Yoshida, Masayuki Watanabe, M. Nakao, H. Baba (2018)
Nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen speciesThe Journal of Pathology, 244
S. Itoh, T. Yoshizumi, Y. Kitamura, K. Yugawa, Norifumi Iseda, Tomonari Shimagaki, Y. Nagao, T. Toshima, N. Harada, Kenichi Kohashi, S. Baba, K. Ishigami, Y. Oda, M. Mori (2021)
Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular FormationHepatology Communications, 5
R. Finn, S. Qin, M. Ikeda, P. Galle, M. Ducreux, Tae-You Kim, M. Kudo, V. Breder, P. Merle, A. Kaseb, Daneng Li, W. Verret, Derek-Zhen Xu, S. Hernandez, Juan Liu, Chen Huang, S. Mulla, Yulei Wang, Ho Lim, A. Zhu, A. Cheng (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.The New England journal of medicine, 382 20
C. Caracó, L. Aloj, Li‐Yuan Chen, J. Chou, W. Eckelman (2000)
Cellular Release of [18F]2-Fluoro-2-deoxyglucose as a Function of the Glucose-6-phosphatase Enzyme System*The Journal of Biological Chemistry, 275
Aconitase 1; ACO2, Aconitase 2; ACTB
M. Ludtmann, Plamena Angelova, Ying Zhang, A. Abramov, A. Dinkova-Kostova (2014)
Nrf2 affects the efficiency of mitochondrial fatty acid oxidation.The Biochemical journal, 457 3
T. Torizuka, N. Tamaki, K. Kasagi, T. Misaki, M. Kawamoto, E. Tadamura, Y. Magata, Y. Yonekura, T. Mori, J. Konishi (1995)
Myocardial oxidative metabolism in hyperthyroid patients assessed by PET with carbon-11-acetate.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 36 11
S. Homma, Yukio Ishii, Y. Morishima, Tadahiro Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, K. Itoh, Masayuki Yamamoto (2009)
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung CancerClinical Cancer Research, 15
Kinase Catalytic Subunit Gamma 2; PRPS1, Phosphoribosyl Pyrophosphate Synthetase 1
K. Yugawa, S. Itoh, T. Yoshizumi, Norifumi Iseda, T. Tomiyama, A. Morinaga, T. Toshima, N. Harada, Kenichi Kohashi, Y. Oda, M. Mori (2020)
CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular CarcinomaHepatology Communications, 5
P. Yuan, Tao Yang, J. Mu, J. Zhao, Yi Yang, Zhaoyong Yan, Yiran Hou, Cheng Chen, J. Xing, Hongxin Zhang, Jibin Li (2019)
Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells.Cancer letters
A. Sacher, L. Gandhi (2016)
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.JAMA oncology, 2 9
Glyceraldehyde-3-Phosphate Dehydrogenase; GBE1, 1,4-Alpha-Glucan Branching Enzyme 1
Non-Catalytic Subunit Gamma
S. Itoh, K. Shirabe, Yoshihiro Matsumoto, S. Yoshiya, J. Muto, N. Harimoto, Y. Yamashita, T. Ikegami, T. Yoshizumi, A. Nishie, Y. Maehara (2014)
Effect of Body Composition on Outcomes after Hepatic Resection for Hepatocellular CarcinomaAnnals of Surgical Oncology, 21
Sarah Lacher, Daniel Levings, S. Freeman, Matthew Slattery (2018)
Identification of a functional antioxidant response element at the HIF1A locusRedox Biology, 19
(2021)
Impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formationHepatol Commun
Pyrophosphate Synthetase 2; PYGL, Glycogen Phosphorylase L
(2019)
Hepatocellular carcinomaN Engl J Med, 380
Synthase Kinase 3 Beta; GYS1, Glycogen Synthase 1
Yiyu Lu, Ting Shen, Hua Yang, W. Gu (2016)
Ruthenium Complexes Induce HepG2 Human Hepatocellular Carcinoma Cell Apoptosis and Inhibit Cell Migration and Invasion through Regulation of the Nrf2 PathwayInternational Journal of Molecular Sciences, 17
M. Noman, S. Chouaib (2014)
Targeting hypoxia at the forefront of anticancer immune responsesOncoImmunology, 3
Y. Mitsuishi, K. Taguchi, Y. Kawatani, T. Shibata, T. Nukiwa, H. Aburatani, Masayuki Yamamoto, H. Motohashi (2012)
Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.Cancer cell, 22 1
I. Barsoum, M. Koti, D. Siemens, C. Graham (2014)
Mechanisms of hypoxia-mediated immune escape in cancer.Cancer research, 74 24
H. Kitamura, H. Motohashi (2018)
NRF2 addiction in cancer cellsCancer Science, 109
S. Itoh, K. Morita, S. Ueda, K. Sugimachi, Y. Yamashita, T. Gion, K. Fukuzawa, K. Wakasugi, A. Taketomi, Y. Maehara (2009)
Long-Term Results of Hepatic Resection Combined with Intraoperative Local Ablation Therapy for Patients with Multinodular Hepatocellular CarcinomasAnnals of Surgical Oncology, 16
A. Achari, S. Marshall, H. Muirhead, R. Palmieri, E. Noltmann (1981)
Glucose-6-phosphate isomerase.Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 293 1063
Glucose-6-Phosphatase Catalytic Subunit 3; G6PD, Glucose-6-Phosphate Dehydrogenase
Hypoxanthine Phosphoribosyltransferase 1; IDH1, Isocitrate Dehydrogenase
Dehydrogenase Kinase 2; PDK3, Pyruvate Dehydrogenase Kinase 3; PDK4, Pyruvate Dehydrogenase Kinase 4
M. Sporn, K. Liby (2012)
NRF2 and cancer: the good, the bad and the importance of contextNature Reviews Cancer, 12
G. DeNicola, F. Karreth, Timothy Humpton, A. Gopinathan, Cong Wei, K. Frese, Dipti Mangal, Kenneth Yu, C. Yeo, E. Calhoun, F. Scrimieri, J. Winter, R. Hruban, C. Iacobuzio-Donahue, S. Kern, I. Blair, D. Tuveson (2011)
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesisNature, 475
Bishnuhari Paudyal, P. Paudyal, N. Oriuchi, Y. Tsushima, T. Nakajima, K. Endo (2008)
Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.International journal of oncology, 33 5
Wen-rong Gong, Q. Song, Xiaoming Lu, W. Gong, Jianhua Zhao, Pengxiang Min, X. Yi (2011)
Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK PathwayJournal of Chemotherapy, 23
Catalytic Subunit Alpha; IDH3B, Isocitrate Dehydrogenase (NAD(+)) 3 Non-Catalytic Subunit Beta
We examined phosphorylated nuclear factor erythroid 2–related factor 2 (P‐NRF2) expression in surgically resected primary hepatocellular carcinoma (HCC) and investigated the association of P‐NRF2 expression with clinicopathological features and patient outcome. We also evaluated the relationship among NRF2, cancer metabolism, and programmed death ligand 1 (PD‐L1) expression. In this retrospective study, immunohistochemical staining of P‐NRF2 was performed on the samples of 335 patients who underwent hepatic resection for HCC. Tomography/computed tomography using fluorine‐18 fluorodeoxyglucose was performed, and HCC cell lines after NRF2 knockdown were analyzed by array. We also analyzed the expression of PD‐L1 after hypoxia inducible factor 1α (HIF1A) knockdown in NRF2‐overexpressing HCC cell lines. Samples from 121 patients (36.1%) were positive for P‐NRF2. Positive P‐NRF2 expression was significantly associated with high alpha‐fetoprotein (AFP) expression, a high rate of poor differentiation, and microscopic intrahepatic metastasis. In addition, positive P‐NRF2 expression was an independent predictor for recurrence‐free survival and overall survival. NRF2 regulated glucose transporter 1, hexokinase 2, pyruvate kinase isoenzymes L/R, and phosphoglycerate kinase 1 expression and was related to the maximum standardized uptake value. PD‐L1 protein expression levels were increased through hypoxia‐inducible factor 1α after NRF2 overexpression in HCC cells. Conclusions: Our large cohort study revealed that P‐NRF2 expression in cancer cells was associated with clinical outcome in HCC. Additionally, we found that NRF2 was located upstream of cancer metabolism and tumor immunity.
Hepatology Communications – Wolters Kluwer Health
Published: Apr 23, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.